Jonathan D Edgeworth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4880786/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical Microbiology and Infection, 2022, 28, 93-100.	2.8	21
2	SARS-CoV-2 variants with shortened incubation periods necessitate new definitions for nosocomial acquisition. Journal of Infection, 2022, 84, 248-288.	1.7	6
3	Association of cardiometabolic microRNAs with COVID-19 severity and mortality. Cardiovascular Research, 2022, 118, 461-474.	1.8	51
4	Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice. IScience, 2021, 24, 102479.	1.9	29
5	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nature Communications, 2021, 12, 3406.	5.8	122
6	Development and evaluation of a nanopore 16S rRNA gene sequencing service for same day targeted treatment of bacterial respiratory infection in the intensive care unit. Journal of Infection, 2021, 83, 167-174.	1.7	16
7	Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe, The, 2021, 2, e461-e471.	3.4	109
8	Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants. Lancet Infectious Diseases, The, 2021, 21, 1351-1352.	4.6	18
9	Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units. Genome Medicine, 2021, 13, 182.	3.6	32
10	Acute kidney injury as a risk factor of hyperactive delirium: A case control study. Journal of Critical Care, 2020, 55, 194-197.	1.0	12
11	Translational Research in the Time of COVID-19—Dissolving Boundaries. PLoS Pathogens, 2020, 16, e1008898.	2.1	7
12	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	5.9	1,115
13	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	2.1	105
14	Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol. Systematic Reviews, 2020, 9, 131.	2.5	8
15	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst, The, 2020, 145, 5638-5646.	1.7	26
16	Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 2019, 68, 1932-1934.	2.9	49
17	Expanding the Reach of Critical Care Pharmacists Globally*. Critical Care Medicine, 2018, 46, 328-330.	0.4	8
18	Critical care pharmacy workforce: UK deployment and characteristics in 2015. International Journal of Pharmacy Practice, 2018, 26, 325-333.	0.3	16

#	Article	IF	CITATIONS
19	Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT. Health Technology Assessment, 2018, 22, 1-148.	1.3	10
20	PROTECTED-UK – Clinical pharmacist interventions in the UK critical care unit: exploration of relationship between intervention, service characteristics and experience level. International Journal of Pharmacy Practice, 2017, 25, 311-319.	0.3	20
21	Paracetamol in intensive care – intravenous, oral or not at all?. Anaesthesia, 2016, 71, 1136-1140.	1.8	3
22	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
23	Corticosteroids in Delirium. Critical Care Medicine, 2015, 43, 2703-2704.	0.4	1
24	Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically III Patients. Medicine (United States), 2015, 94, e1479.	0.4	11
25	Pharmacist's review and outcomes: Treatment-enhancing contributions tallied, evaluated, and documented (PROTECTED-UK). Journal of Critical Care, 2015, 30, 808-813.	1.0	46
26	A web-based survey of United Kingdom sedation practice in the intensive care unit. Journal of Critical Care, 2015, 30, 436.e1-436.e6.	1.0	30
27	The influence of statin exposure on inflammatory markers in patients with early bacterial infection: pilot prospective cohort study. BMC Anesthesiology, 2014, 14, 106.	0.7	5
28	Nonleg Venous Thrombosis in Critically III Adults. JAMA Internal Medicine, 2014, 174, 689.	2.6	43
29	Long-term adherence to a 5 day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2014, 69, 1688-1694.	1.3	7
30	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	1.1	48
31	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	2.9	843
32	Levosimendan: A retrospective single-center case series. Journal of Critical Care, 2013, 28, 1075-1078.	1.0	6
33	Clustering of Antimicrobial Resistance Outbreaks Across Bacterial Species in the Intensive Care Unit. Clinical Infectious Diseases, 2013, 57, 65-76.	2.9	18
34	Beyond the Randomized Clinical Trial: Citrate for Continuous Renal Replacement Therapy in Clinical Practice. Nephron Clinical Practice, 2013, 124, 119-123.	2.3	9
35	Maintaining Normal Levels of Ionized Calcium during Citrate-Based Renal Replacement Therapy Is Associated with Stable Parathyroid Hormone Levels. Nephron Clinical Practice, 2013, 124, 124-131.	2.3	15
36	Management of long-term hypothyroidism: a potential marker of quality of medicines reconciliation in the intensive care unitâ€. International Journal of Pharmacy Practice, 2012, 20, 303-306.	0.3	17

Jonathan D Edgeworth

#	Article	IF	CITATIONS
37	Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study. Intensive Care Medicine, 2012, 38, 1683-1688.	3.9	11
38	Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years. Journal of Critical Care, 2012, 27, 320.e7-320.e12.	1.0	1
39	Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series. Critical Care, 2011, 15, R159.	2.5	14
40	Antibiotic dosing in critical illness. Journal of Antimicrobial Chemotherapy, 2011, 66, ii25-ii31.	1.3	92
41	Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. Journal of Antimicrobial Chemotherapy, 2011, 66, ii41-ii47.	1.3	53
42	Sedation versus no sedation in the intensive-care unit. Lancet, The, 2010, 375, 1159.	6.3	2
43	A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. European Journal of Haematology, 2007, 78, 532-539.	1.1	63
44	Between benzodiazepine over-sedation and neurological damage. Critical Care, 2005, 9, 303.	2.5	5
45	Continuous venovenous haemofiltration for the treatment of theophylline toxicity. Thorax, 2001, 56, 242-243.	2.7	15
46	A 25-year study of nosocomial bacteremia in an adult intensive care unit. Critical Care Medicine, 1999, 27, 1421-1428.	0.4	161